Neuroinflammation in Alzheimer's disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zhang, 2013, Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease, Cell, 153, 707, 10.1016/j.cell.2013.03.030
Guerreiro, 2013, TREM2 variants in Alzheimer's disease, N Engl J Med, 368, 117, 10.1056/NEJMoa1211851
Bradshaw, 2013, CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology, Nat Neurosci, 16, 848, 10.1038/nn.3435
Griciuc, 2013, Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta, Neuron, 78, 631, 10.1016/j.neuron.2013.04.014
Ji, 2013, Microglia actively regulate the number of functional synapses, PLoS One, 8, e56293, 10.1371/journal.pone.0056293
Parkhurst, 2013, Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor, Cell, 155, 1596, 10.1016/j.cell.2013.11.030
Bamberger, 2003, A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation, J Neurosci, 23, 2665, 10.1523/JNEUROSCI.23-07-02665.2003
Paresce, 1996, Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor, Neuron, 17, 553, 10.1016/S0896-6273(00)80187-7
Stewart, 2010, CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer, Nat Immunol, 11, 155, 10.1038/ni.1836
Liu, 2005, LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide, Brain, 128, 1778, 10.1093/brain/awh531
Kummer, 2014, Truncated and modified amyloid-beta species, Alzheimers Res Ther, 6, 28, 10.1186/alzrt258
El Khoury, 2003, CD36 mediates the innate host response to beta-amyloid, J Exp Med, 197, 1657, 10.1084/jem.20021546
Sheedy, 2013, CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation, Nat Immunol, 14, 812, 10.1038/ni.2639
Lee, 2010, The role of microglia in amyloid clearance from the AD brain, J Neural Transm, 117, 949, 10.1007/s00702-010-0433-4
Mawuenyega, 2010, Decreased clearance of CNS β-amyloid in Alzheimer's disease, Science, 330, 1774, 10.1126/science.1197623
Hickman, 2008, Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice, J Neurosci, 28, 8354, 10.1523/JNEUROSCI.0616-08.2008
Frank, 2008, TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice, Glia, 56, 1438, 10.1002/glia.20710
Hickman, 2013, The microglial sensome revealed by direct RNA sequencing, Nat Neurosci, 16, 1896, 10.1038/nn.3554
Hsieh, 2009, A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia, J Neurochem, 109, 1144, 10.1111/j.1471-4159.2009.06042.x
Sierra-Filardi, 2011, Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers, Blood, 117, 5092, 10.1182/blood-2010-09-306993
Colton, 2006, Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD, J Neuroinflammation, 3, 27, 10.1186/1742-2094-3-27
Mantovani, 2004, The chemokine system in diverse forms of macrophage activation and polarization, Trends Immunol, 25, 677, 10.1016/j.it.2004.09.015
Mantovani, 2002, Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol, 23, 549, 10.1016/S1471-4906(02)02302-5
Koenigsknecht-Talboo, 2005, Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines, J Neurosci, 25, 8240, 10.1523/JNEUROSCI.1808-05.2005
Goerdt, 1999, Other functions, other genes: alternative activation of antigen-presenting cells, Immunity, 10, 137, 10.1016/S1074-7613(00)80014-X
Zelcer, 2007, Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors, Proc Natl Acad Sci USA, 104, 10601, 10.1073/pnas.0701096104
Colton, 2010, Assessing activation states in microglia, CNS Neurol Disord Drug Targets, 9, 174, 10.2174/187152710791012053
Town, 2008, Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology, Nat Med, 14, 681, 10.1038/nm1781
Xue, 2014, Transcriptome-based network analysis reveals a spectrum model of human macrophage activation, Immunity, 40, 274, 10.1016/j.immuni.2014.01.006
Perry, 2013, Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration, Semin Immunopathol, 35, 601, 10.1007/s00281-013-0382-8
Orre, 2013, Reactive glia show increased immunoproteasome activity in Alzheimer's disease, Brain, 136, 1415, 10.1093/brain/awt083
Simard, 2006, Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease, Neuron, 49, 489, 10.1016/j.neuron.2006.01.022
El Khoury, 2007, Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease, Nat Med, 13, 432, 10.1038/nm1555
Mildner, 2011, Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease, J Neurosci, 31, 11159, 10.1523/JNEUROSCI.6209-10.2011
Hawkes, 2009, Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy, Proc Natl Acad Sci USA, 106, 1261, 10.1073/pnas.0805453106
Ginhoux, 2010, Fate mapping analysis reveals that adult microglia derive from primitive macrophages, Science, 330, 841, 10.1126/science.1194637
Grathwohl, 2009, Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia, Nat Neurosci, 12, 1361, 10.1038/nn.2432
Streit, 2009, Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease, Acta Neuropathol, 118, 475, 10.1007/s00401-009-0556-6
Krabbe, 2013, Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology, PLoS One, 8, e60921, 10.1371/journal.pone.0060921
Lucin, 2013, Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease, Neuron, 79, 873, 10.1016/j.neuron.2013.06.046
Yamanaka, 2012, PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice, J Neurosci, 32, 17321, 10.1523/JNEUROSCI.1569-12.2012
Cramer, 2012, ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models, Science, 335, 1503, 10.1126/science.1217697
Fitz, 2013, Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”, Science, 340, 924, 10.1126/science.1235809
Price, 2013, Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”, Science, 340, 924, 10.1126/science.1234089
Tesseur, 2013, Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse 'models”, Science, 340, 924, 10.1126/science.1233937
Veeraraghavalu, 2013, Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”, Science, 340, 924, 10.1126/science.1235505
Sofroniew, 2009, Molecular dissection of reactive astrogliosis and glial scar formation, Trends Neurosci, 32, 638, 10.1016/j.tins.2009.08.002
Sofroniew, 2010, Astrocytes: biology and pathology, Acta Neuropathol, 119, 7, 10.1007/s00401-009-0619-8
Medeiros, 2013, Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony, Exp Neurol, 239, 133, 10.1016/j.expneurol.2012.10.007
Olabarria, 2010, Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease, Glia, 58, 831, 10.1002/glia.20967
Kummer, 2014, Ear2 deletion causes early memory and learning deficits in APP/PS1 mice, J Neurosci, 34, 8845, 10.1523/JNEUROSCI.4027-13.2014
Olabarria, 2011, Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission?, Mol Neurodegener, 6, 55, 10.1186/1750-1326-6-55
Yeh, 2011, Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease, ASN Neuro, 3, 271, 10.1042/AN20110025
Kulijewicz-Nawrot, 2012, Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease, J Anat, 221, 252, 10.1111/j.1469-7580.2012.01536.x
Beauquis, 2013, Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease, Exp Neurol, 239, 28, 10.1016/j.expneurol.2012.09.009
Furman, 2012, Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease, J Neurosci, 32, 16129, 10.1523/JNEUROSCI.2323-12.2012
Wyss-Coray, 2003, Adult mouse astrocytes degrade amyloid-beta in vitro and in situ, Nat Med, 9, 453, 10.1038/nm838
Koistinaho, 2004, Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides, Nat Med, 10, 719, 10.1038/nm1058
Jiang, 2008, ApoE promotes the proteolytic degradation of Aβ, Neuron, 58, 681, 10.1016/j.neuron.2008.04.010
Terwel, 2011, Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis, J Neurosci, 31, 7049, 10.1523/JNEUROSCI.6546-10.2011
Saido, 2012, Proteolytic degradation of amyloid β-protein, Cold Spring Harb Perspect Med, 2, a006379, 10.1101/cshperspect.a006379
Pihlaja, 2011, Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes, Glia, 59, 1643, 10.1002/glia.21212
Iliff, 2012, A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β, Sci Transl Med, 4, 147ra111, 10.1126/scitranslmed.3003748
Patel, 2005, Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease, J Neuroinflammation, 2, 9, 10.1186/1742-2094-2-9
Lue, 2001, Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro, Glia, 35, 72, 10.1002/glia.1072
Laske, 2010, Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease, Curr Alzheimer Res, 7, 409, 10.2174/156720510791383813
Heneka, 2014, Innate immune activation in neurodegenerative disease, Nat Rev Immunol, 14, 463, 10.1038/nri3705
Heneka, 2013, NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice, Nature, 493, 674, 10.1038/nature11729
Akama, 2000, β-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β- and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFα receptor-associated factor- and NFκB-inducing kinase-dependent signaling mechanism, J Biol Chem, 275, 7918, 10.1074/jbc.275.11.7918
Mrak, 1995, Glial cytokines in Alzheimer's disease: review and pathogenic implications, Hum Pathol, 26, 816, 10.1016/0046-8177(95)90001-2
Vom Berg, 2012, Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline, Nat Med, 18, 1812, 10.1038/nm.2965
Tan, 2014, IL12/23 p40 inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in SAMP8 mice, J Alzheimers Dis, 38, 633, 10.3233/JAD-131148
Rentzos, 2006, Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia, J Neurol Sci, 249, 110, 10.1016/j.jns.2006.05.063
Tarkowski, 2003, Intrathecal inflammation precedes development of Alzheimer's disease, J Neurol Neurosurg Psychiatry, 74, 1200, 10.1136/jnnp.74.9.1200
Meda, 1995, Activation of microglial cells by β-amyloid protein and interferon- γ, Nature, 374, 647, 10.1038/374647a0
Tan, 1999, Microglial activation resulting from CD40–CD40L interaction after beta-amyloid stimulation, Science, 286, 2352, 10.1126/science.286.5448.2352
Tan, 2002, Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice, Nat Neurosci, 5, 1288, 10.1038/nn968
Jin, 2008, Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease, J Neuroinflammation, 5, 23, 10.1186/1742-2094-5-23
Shaftel, 2007, Chronic interleukin-1β expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration, J Neurosci, 27, 9301, 10.1523/JNEUROSCI.1418-07.2007
Ghosh, 2013, Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model, J Neurosci, 33, 5053, 10.1523/JNEUROSCI.4361-12.2013
Chakrabarty, 2010, IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice, J Immunol, 184, 5333, 10.4049/jimmunol.0903382
Chakrabarty, 2010, Massive gliosis induced by interleukin-6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition, FASEB J, 24, 548, 10.1096/fj.09-141754
Chakrabarty, 2011, Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo, Mol Neurodegener, 6, 16, 10.1186/1750-1326-6-16
Chakrabarty, 2012, Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition, Mol Neurodegener, 7, 36, 10.1186/1750-1326-7-36
Savarin-Vuaillat, 2007, Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?, Neurotherapeutics, 4, 590, 10.1016/j.nurt.2007.07.004
Xia, 1998, Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains, Am J Pathol, 153, 31, 10.1016/S0002-9440(10)65542-3
Ishizuka, 1997, Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease, Psychiatry Clin Neurosci, 51, 135, 10.1111/j.1440-1819.1997.tb02375.x
Smits, 2002, Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes, J Neuroimmunol, 127, 160, 10.1016/S0165-5728(02)00112-1
Lue, 2001, Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures, Neurobiol Aging, 22, 945, 10.1016/S0197-4580(01)00311-6
Fuhrmann, 2010, Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease, Nat Neurosci, 13, 411, 10.1038/nn.2511
Lee, 2010, CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models, Am J Pathol, 177, 2549, 10.2353/ajpath.2010.100265
Cho, 2011, CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease, J Biol Chem, 286, 32713, 10.1074/jbc.M111.254268
Lee, 2009, CCR5 deficiency induces astrocyte activation, Aβ deposit and impaired memory function, Neurobiol Learn Mem, 92, 356, 10.1016/j.nlm.2009.04.003
Kiyota, 2009, CCL2 accelerates microglia-mediated Aβ oligomer formation and progression of neurocognitive dysfunction, PLoS One, 4, e6197, 10.1371/journal.pone.0006197
Semple, 2010, CCL2 modulates cytokine production in cultured mouse astrocytes, J Neuroinflammation, 7, 67, 10.1186/1742-2094-7-67
van de Veerdonk, 2011, Inflammasome activation and IL-1β and IL-18 processing during infection, Trends Immunol, 32, 110, 10.1016/j.it.2011.01.003
Halle, 2008, The NALP3 inflammasome is involved in the innate immune response to amyloid-β, Nat Immunol, 9, 857, 10.1038/ni.1636
Fricker, 2013, Caspase inhibitors protect neurons by enabling selective necroptosis of inflamed microglia, J Biol Chem, 288, 9145, 10.1074/jbc.M112.427880
Burguillos, 2011, Caspase signalling controls microglia activation and neurotoxicity, Nature, 472, 319, 10.1038/nature09788
Rohn, 2009, Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh, Int J Clin Exp Med, 2, 300
Biscaro, 2012, Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease, Neurodegener Dis, 9, 187, 10.1159/000330363
Choi, 2013, Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease, J Neurochem, 124, 59, 10.1111/jnc.12059
Montine, 1999, Elevated CSF prostaglandin E2 levels in patients with probable AD, Neurology, 53, 1495, 10.1212/WNL.53.7.1495
Slawik, 2004, Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum, Neurochem Int, 45, 653, 10.1016/j.neuint.2004.04.007
Shie, 2005, Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons, Brain Pathol, 15, 134, 10.1111/j.1750-3639.2005.tb00509.x
Liang, 2005, Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease, J Neurosci, 25, 10180, 10.1523/JNEUROSCI.3591-05.2005
Shi, 2012, Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease, Ann Neurol, 72, 788, 10.1002/ana.23677
Xiang, 2002, Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology, Gene Expr, 10, 271, 10.3727/000000002783992352
Woodling, 2014, Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling, J Neurosci, 34, 5882, 10.1523/JNEUROSCI.0410-14.2014
Bazan, 2011, Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases, Annu Rev Nutr, 31, 321, 10.1146/annurev.nutr.012809.104635
Lukiw, 2005, A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease, J Clin Invest, 115, 2774, 10.1172/JCI25420
Zhao, 2011, Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models, PLoS One, 6, e15816, 10.1371/journal.pone.0015816
Strohmeyer, 2002, Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain, J Neuroimmunol, 131, 135, 10.1016/S0165-5728(02)00272-2
Lambert, 2009, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, Nat Genet, 41, 1094, 10.1038/ng.439
Harold, 2009, Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, Nat Genet, 41, 1088, 10.1038/ng.440
Vodovotz, 1996, Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease, J Exp Med, 184, 1425, 10.1084/jem.184.4.1425
Nathan, 2005, Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase, J Exp Med, 202, 1163, 10.1084/jem.20051529
Jekabsone, 2006, Fibrillar β-amyloid peptide Aβ1–40 activates microglial proliferation via stimulating TNF-α release and H2O2 derived from NADPH oxidase: a cell culture study, J Neuroinflammation, 3, 24, 10.1186/1742-2094-3-24
Choi, 2012, Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation, J Neurochem, 120, 292, 10.1111/j.1471-4159.2011.07572.x
Mander, 2005, Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration, J Neuroinflammation, 2, 20, 10.1186/1742-2094-2-20
Butterfield, 2007, Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease, Brain Res, 1148, 243, 10.1016/j.brainres.2007.02.084
Kummer, 2011, Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation, Neuron, 71, 833, 10.1016/j.neuron.2011.07.001
Thiabaud, 2013, Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress, Angew Chem Int Ed Engl, 52, 8041, 10.1002/anie.201302989
Cho, 2009, S-nitrosylation of Drp1 mediates β-amyloid-related mitochondrial fission and neuronal injury, Science, 324, 102, 10.1126/science.1171091
Iadecola, 2004, Neurovascular regulation in the normal brain and in Alzheimer's disease, Nat Rev Neurosci, 5, 347, 10.1038/nrn1387
Shin, 2007, Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy, Brain, 130, 2310, 10.1093/brain/awm156
Petzold, 2011, Role of astrocytes in neurovascular coupling, Neuron, 71, 782, 10.1016/j.neuron.2011.08.009
Jarre, 2014, Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease, Cell Signal, 26, 2040, 10.1016/j.cellsig.2014.05.019
Deane, 2003, RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain, Nat Med, 9, 907, 10.1038/nm890
Zlokovic, 2011, Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders, Nat Rev Neurosci, 12, 723, 10.1038/nrn3114
Hart, 1988, Biological basis of the behavior of sick animals, Neurosci Biobehav Rev, 12, 123, 10.1016/S0149-7634(88)80004-6
Yang, 2004, Reversing established sepsis with antagonists of endogenous high-mobility group box 1, Proc Natl Acad Sci USA, 101, 296, 10.1073/pnas.2434651100
Rivest, 2009, Regulation of innate immune responses in the brain, Nat Rev Immunol, 9, 429, 10.1038/nri2565
Undén, 2007, Inflammatory cytokines, behaviour and age as determinants of self-rated health in women, Clin Sci (Lond), 112, 363, 10.1042/CS20060128
Maitra, 2012, Molecular mechanisms responsible for the selective and low-grade induction of proinflammatory mediators in murine macrophages by lipopolysaccharide, J Immunol, 189, 1014, 10.4049/jimmunol.1200857
Pace, 1983, Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing, J Immunol, 130, 2011, 10.4049/jimmunol.130.5.2011
Godbout, 2009, Age and neuroinflammation: a lifetime of psychoneuroimmune consequences, Immunol Allergy Clin North Am, 29, 321, 10.1016/j.iac.2009.02.007
Cunningham, 2005, Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration, J Neurosci, 25, 9275, 10.1523/JNEUROSCI.2614-05.2005
Cunningham, 2009, Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease, Biol Psychiatry, 65, 304, 10.1016/j.biopsych.2008.07.024
Field, 2010, Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration, Brain Behav Immun, 24, 996, 10.1016/j.bbi.2010.04.004
Kyrkanides, 2011, Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice, J Neuroinflammation, 8, 112, 10.1186/1742-2094-8-112
Holmes, 2009, Systemic inflammation and disease progression in Alzheimer disease, Neurology, 73, 768, 10.1212/WNL.0b013e3181b6bb95
Holmes, 2011, Proinflammatory cytokines, sickness behavior, and Alzheimer disease, Neurology, 77, 212, 10.1212/WNL.0b013e318225ae07
Almond, 2013, Obesity and susceptibility to severe outcomes following respiratory viral infection, Thorax, 68, 684, 10.1136/thoraxjnl-2012-203009
Chidiac, 2012, Pneumococcal infections and adult with risk factors, Med Mal Infect, 42, 517, 10.1016/j.medmal.2012.04.003
Bastard, 2006, Recent advances in the relationship between obesity, inflammation, and insulin resistance, Eur Cytokine Netw, 17, 4
Whitmer, 2008, Central obesity and increased risk of dementia more than three decades later, Neurology, 71, 1057, 10.1212/01.wnl.0000306313.89165.ef
Brown, 2013, Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?, Mol Psychiatry, 18, 864, 10.1038/mp.2012.162
Takeda, 2010, Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes, Proc Natl Acad Sci USA, 107, 7036, 10.1073/pnas.1000645107
Le Chatelier, 2013, Richness of human gut microbiome correlates with metabolic markers, Nature, 500, 541, 10.1038/nature12506
Sivanandam, 2012, Traumatic brain injury: a risk factor for Alzheimer's disease, Neurosci Biobehav Rev, 36, 1376, 10.1016/j.neubiorev.2012.02.013
Brody, 2006, Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury, Exp Neurol, 197, 330, 10.1016/j.expneurol.2005.10.020
Tajiri, 2013, Traumatic brain injury precipitates cognitive impairment and extracellular Aβ aggregation in Alzheimer's disease transgenic mice, PLoS One, 8, e78851, 10.1371/journal.pone.0078851
Koshinaga, 2000, Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices, J Neurotrauma, 17, 185, 10.1089/neu.2000.17.185
Ramlackhansingh, 2011, Inflammation after trauma: microglial activation and traumatic brain injury, Ann Neurol, 70, 374, 10.1002/ana.22455
Sastre, 2003, Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase, J Neurosci, 23, 9796, 10.1523/JNEUROSCI.23-30-09796.2003
Corrigan, 2011, The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains, Brain Res, 1378, 137, 10.1016/j.brainres.2010.12.077
O'Donnell, 2012, Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance, Neurochem Res, 37, 2496, 10.1007/s11064-012-0818-x
Marien, 2004, Noradrenergic mechanisms in neurodegenerative diseases: a theory, Brain Res Brain Res Rev, 45, 38, 10.1016/j.brainresrev.2004.02.002
Zarow, 2003, Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases, Arch Neurol, 60, 337, 10.1001/archneur.60.3.337
Kalinin, 2007, Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease, Neurobiol Aging, 28, 1206, 10.1016/j.neurobiolaging.2006.06.003
Heneka, 2006, Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice, J Neurosci, 26, 1343, 10.1523/JNEUROSCI.4236-05.2006
O'Sullivan, 2010, Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge, J Neuroimmunol, 220, 34, 10.1016/j.jneuroim.2009.12.007
Kalinin, 2012, The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease, Neurobiol Aging, 33, 1651, 10.1016/j.neurobiolaging.2011.04.012
Bolmont, 2008, Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance, J Neurosci, 28, 4283, 10.1523/JNEUROSCI.4814-07.2008
Meyer-Luehmann, 2006, Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host, Science, 313, 1781, 10.1126/science.1131864
Kim, 2006, Innate response to focal necrotic injury inside the blood-brain barrier, J Immunol, 177, 5269, 10.4049/jimmunol.177.8.5269
Perry, 2010, Microglia in neurodegenerative disease, Nat Rev Neurol, 6, 193, 10.1038/nrneurol.2010.17
Rupprecht, 2010, Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders, Nat Rev Drug Discov, 9, 971, 10.1038/nrd3295
Jacobs, 2012, Noninvasive molecular imaging of neuroinflammation, J Cereb Blood Flow Metab, 32, 1393, 10.1038/jcbfm.2012.53
Venneti, 2009, PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET, Neurobiol Aging, 30, 1217, 10.1016/j.neurobiolaging.2007.11.005
Roberts, 2009, Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice, Exp Neurol, 216, 459, 10.1016/j.expneurol.2009.01.002
Rapic, 2013, Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease, Neurobiol Aging, 34, 351, 10.1016/j.neurobiolaging.2012.04.016
Heneka, 2011, Impact and Therapeutic Potential of PPARs in Alzheimer's Disease, Curr Neuropharmacol, 9, 643, 10.2174/157015911798376325
Chauveau, 2011, In vivo imaging of neuroinflammation in the rodent brain with [11C]SSR180575, a novel indoleacetamide radioligand of the translocator protein (18 kDa), Eur J Nucl Med Mol Imaging, 38, 509, 10.1007/s00259-010-1628-5
Chauveau, 2009, Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation, J Nucl Med, 50, 468, 10.2967/jnumed.108.058669
Schuitemaker, 2013, Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study, Neurobiol Aging, 34, 128, 10.1016/j.neurobiolaging.2012.04.021
Yasuno, 2012, Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [11C]DAA1106, Psychiatry Res, 203, 67, 10.1016/j.pscychresns.2011.08.013
Edison, 2007, Relationship between the distribution of microglial activation and amyloid deposition in Alzheimer's disease: An 11C–PK11195 and 11C-PIB PET study, J Neurol Neurosurg Psychiatry, 78, 219
Yokokura, 2011, In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease, Eur J Nucl Med Mol Imaging, 38, 343, 10.1007/s00259-010-1612-0
Edison, 2007, Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study, Neurology, 68, 501, 10.1212/01.wnl.0000244749.20056.d4
Kreisl, 2013, In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease, Brain, 136, 2228, 10.1093/brain/awt145
Okello, 2009, Microglial activation and amyloid deposition in mild cognitive impairment: a PET study, Neurology, 72, 56, 10.1212/01.wnl.0000338622.27876.0d
Shi, 2012, Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS), Neurobiol Aging, 33, 1849.e5, 10.1016/j.neurobiolaging.2012.02.014
Brosseron, 2014, Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview, Mol Neurobiol, 50, 534, 10.1007/s12035-014-8657-1
Galimberti, 2008, Inflammation in neurodegenerative disorders: friend or foe?, Curr Aging Sci, 1, 30, 10.2174/1874609810801010030
Ruckh, 2012, Rejuvenation of regeneration in the aging central nervous system, Cell Stem Cell, 10, 96, 10.1016/j.stem.2011.11.019
Villeda, 2008, Microglia—a wrench in the running wheel?, Neuron, 59, 527, 10.1016/j.neuron.2008.08.005
Lista, 2013, Biological and methodical challenges of blood-based proteomics in the field of neurological research, Prog Neurobiol, 101–102, 18, 10.1016/j.pneurobio.2012.06.006
Green, 2011, Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis, Mol Psychiatry, 16, 960, 10.1038/mp.2010.88
Kurita, 2012, Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study, PLoS One, 7, e39212, 10.1371/journal.pone.0039212
Lee, 2007, Decreased plasma BDNF level in depressive patients, J Affect Disord, 101, 239, 10.1016/j.jad.2006.11.005
Martinotti, 2012, Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review, J Biol Regul Homeost Agents, 26, 347
Hu, 2012, Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease, Neurology, 79, 897, 10.1212/WNL.0b013e318266fa70
Ray, 2007, Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins, Nat Med, 13, 1359, 10.1038/nm1653
Soares, 2012, Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease, Arch Neurol, 69, 1310, 10.1001/archneurol.2012.1070
Britschgi, 2011, Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome, Mol Cell Proteomics, 10, 10.1074/mcp.M111.008862
Johnstone, 2012, Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset, PLoS One, 7, e34341, 10.1371/journal.pone.0034341
Rogers, 1993, Clinical trial of indomethacin in Alzheimer's disease, Neurology, 43, 1609, 10.1212/WNL.43.8.1609
de Jong, 2008, No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial, PLoS One, 3, e1475, 10.1371/journal.pone.0001475
Aisen, 2000, A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study, Neurology, 54, 588, 10.1212/WNL.54.3.588
Aisen, 2003, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA, 289, 2819, 10.1001/jama.289.21.2819
Aisen, 2002, Randomized pilot study of nimesulide treatment in Alzheimer's disease, Neurology, 58, 1050, 10.1212/WNL.58.7.1050
Reines, 2004, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology, 62, 66, 10.1212/WNL.62.1.66
Thal, 2005, A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment, Neuropsychopharmacology, 30, 1204, 10.1038/sj.npp.1300690
Van Gool, 2001, Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study, Lancet, 358, 455, 10.1016/S0140-6736(01)05623-9
Martin, 2008, Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib, Arch Neurol, 65, 896, 10.1001/archneur.2008.65.7.nct70006
Lyketsos, 2007, Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial, Neurology, 68, 1800, 10.1212/01.wnl.0000260269.93245.d2
Simons, 2002, Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial, Ann Neurol, 52, 346, 10.1002/ana.10292
Sparks, 2005, Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results, Arch Neurol, 62, 753, 10.1001/archneur.62.5.753
Feldman, 2010, Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe, Neurology, 74, 956, 10.1212/WNL.0b013e3181d6476a
Harrington, 2011, Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies, Curr Alzheimer Res, 8, 592, 10.2174/156720511796391935
Breitner, 2011, Extended results of the Alzheimer's disease anti-inflammatory prevention trial, Alzheimers Dement, 7, 402, 10.1016/j.jalz.2010.12.014
2013, Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimers Dement, 9, 714, 10.1016/j.jalz.2012.11.012
Cribbs, 2012, Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study, J Neuroinflammation, 9, 179, 10.1186/1742-2094-9-179
Shi, 2010, The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity, J Immunol, 184, 7207, 10.4049/jimmunol.0903487
Tang, 2012, Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases, J Cardiovasc Pharmacol, 59, 116, 10.1097/FJC.0b013e3182244a12
Brenneis, 2011, Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation, J Biol Chem, 286, 2331, 10.1074/jbc.M110.157362
Bentham, 2008, Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial, Lancet Neurol, 7, 41, 10.1016/S1474-4422(07)70293-4
Wilcock, 2011, Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses, ASN Neuro, 3, 249, 10.1042/AN20110018
Jimenez, 2008, Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic, J Neurosci, 28, 11650, 10.1523/JNEUROSCI.3024-08.2008
Morgan, 2005, Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics, J Neuropathol Exp Neurol, 64, 743, 10.1097/01.jnen.0000178444.33972.e0
Zotova, 2013, Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization, Brain, 136, 2677, 10.1093/brain/awt210
Boche, 2008, Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain, Brain, 131, 3299, 10.1093/brain/awn261
Wilcock, 2004, Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage, J Neuroinflammation, 1, 24, 10.1186/1742-2094-1-24
Sperling, 2012, Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis, Lancet Neurol, 11, 241, 10.1016/S1474-4422(12)70015-7